MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era.

ABSTRACT:

Background & aims

The Model for End-Stage Liver Disease (MELD) has been established as a reliable indicator of short-term survival in patients with end-stage liver disease. The current version (MELDNa), consisting of the international normalized ratio and serum bilirubin, creatinine, and sodium, has been used to determine organ allocation priorities for liver transplantation in the United States. The objective was to optimize MELD further by taking into account additional variables and updating coefficients with contemporary data.

Methods

All candidates registered on the liver transplant wait list in the US national registry from January 2016 through December 2018 were included. Uni- and multivariable Cox models were developed to predict survival up to 90 days after wait lis

SUBMITTER: Kim WR 

PROVIDER: S-EPMC8608337 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature